Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ABI-007 (paclitaxel) plus ramucirumab in unresectable/recurrent gastric cancer
jRCT2080223034Phase 2
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel and ramucirumab in gastric adenocarcinoma and gastric cancer (GC), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
nab-paclitaxelramucirumab
03
Conditions
gastric adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on jRCT2080223034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223034.